In its first week since going public, Tucson-based ImaRx Therapeutics Inc. found Wall Street investors less than enthusiastic over its stock.

The biotechnology company, which started trading July 26 on the NASDAQ exchange under the symbol IMRX, ended one week of trading closing Aug. 2 at $4.10 per share.

When it first announced its intentions to go public, ImaRx had expected its initial public offering of 3 million shares to price between $6.50 and $7.50 a share, but it lowered that to $5 per share before going public and expected to raise about $12.3 million, after expenses. Trading opened July 26 at $4.90 per share and never trade above that and but went as low as $3.90 per share in its first week. 

Print this story Email this story Post a Comment ADVERTISEMENT

ImaRx Therapeutics, 1635 E. 18th St., is developing therapies for vascular disorders associated with blood clots and strokes using proprietary microbubble technology. It is concentrating most of its efforts on a product named Abbokinase, which is for the treatment of acute massive pulmonary embolism.